Value of the peripheral blood B-cells subsets in patients with ankylosing spondylitis

Chinese Medical Journal

Volumn 122, Issue 15, 2009, Pages 1784-1789

  Lin, Qu ^a   Gu, Jie Ruo ^a   Li, Tian Wang ^a   Zhang, Fu Cheng ^a   Lin, Zhi Ming ^a   Liao, Ze Tao ^a   Wei, Qiu Jing ^a   Cao, Shuang Yan ^a   Li, Li ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Ankylosing; B lymphocyte subsets; Etanercept; Spondylitis

Indexed keywords

CD19 ANTIGEN; CD27 ANTIGEN; ETANERCEPT; PLACEBO;

ADOLESCENT; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; B LYMPHOCYTE; BACKACHE; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPATHOGENESIS; JOINT FUNCTION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MULTICENTER STUDY; PERIPHERAL LYMPHOCYTE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; ANTIGENS, CD19; ANTIGENS, CD27; B-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; YOUNG ADULT;

EID: 70349546194     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.15.013     Document Type: Article

References (22)

1. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48: 1332-1342.
2. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, et al. Disturbed peripheral B-cell homeostasis in systemic lupus erythematosus. J Immunol 2000; 165: 5970-5979.
3. Lindenau S, Scholze S, Odendahl M, Dörner T, Radbruch A, Burmester GR, et al. Aberrant activation of B-cells in patients with rheumatoid arthritis. Ann N Y Acad Sci 2003; 987: 246-248.
4. Toussirot E, Lafforgue P, Boucraut J, Despieds P, Schiano A, Bernard D, et al. Serum levels of interleukin 1-beta, tumor necrosis factor-alpha soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 1994; 13: 175-180.
5. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349-1356.
6. McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-158, iii-iv.
7. Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008; 67: 346-352.
8. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicenter randomized clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594-1600.
9. Van der Linden SJ, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-368.
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
11. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 316-320.
12. Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, Scholze J, et al. Diminished peripheral blood memory B-cells and accumulation of memory B-cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2002; 46: 2160-2171.
13. Appel H, Kuhne M, Spiekermann S, Ebhardt H, Grozdanovic Z, Köhler D, et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006; 54: 2845-2851.
14. Cunnane G, Bresnihan B, FitzGerald O. Immunohistologic analysis of peripheral joint disease in ankylosing spondylitis. Arthritis Rheum 1998; 41: 180-182.
15. Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys EM, De Keyser F. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 2005; 64: 529-536.
16. Voswinkel Jan, Weisgerber K, Pfreundschuh M, Gause A. B-cell involvement in ankylosing spondylitis: the heavychain variable segment gene repertoire of B-cells fromgerminal center-like foci in the synovial membrane indicatesantigen selection. Arthritis Res 2001; 3: 189-195.
17. Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: a memory B-cells maker. Immunol Today 2000; 21: 204-206.
18. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood reveals circulating germinal center founder cells in healthy individuals and disturbance in the B-cells subpopulations in patients with primary Sjogren's syndrome. J Immunol 2001; 167: 3610-3618.
19. Braun J, Baraliakos X, Brandt J, Sieper J. Therapy of ankylosing spondylitis. Part II: Biological therapies in the spondyloarthritides. Scand J Rheumatol 2005; 34: 178-190.
20. Kruithof E, De Rycke L, Roth J, Mielants H, Van den Bosch F, De Keyser F, et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005; 52: 3898-3909.
21. Woo JH, Lee HJ, Sung IH, Kim TH. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007; 34: 1753-1759.
22. Anandarajah A, Ritchlin CT. Treatment update on spondyloarthropathy. Curr Opin Rheumatol 2005; 17: 247-256.